Should the patient with difficulty swallowing bupropion (Wellbutrin) extended‑release 150 mg be switched to bupropion immediate‑release 75 mg twice daily, given she can chew or crush the immediate‑release tablets?

Do Not Switch to Immediate-Release Bupropion

You should not switch this patient from Wellbutrin XL 150 mg to immediate-release bupropion 75 mg twice daily, and the patient must not chew or crush any bupropion formulation. The FDA drug label explicitly states that "Wellbutrin XL should be swallowed whole and not crushed, divided, or chewed" 1. This is a critical safety requirement that applies to all extended-release bupropion formulations.

Why This Switch Is Problematic

Extended-Release Formulations Cannot Be Altered

The extended-release mechanism in Wellbutrin XL is designed to deliver medication gradually over 24 hours, maintaining stable blood levels and minimizing peak-to-trough fluctuations. Crushing, chewing, or dividing these tablets destroys this controlled-release system, potentially causing:

• Immediate release of the entire dose
• Dangerously high peak plasma concentrations
• Significantly increased seizure risk (bupropion's most serious dose-related adverse effect)
• Loss of the tolerability advantages that extended-release formulations provide 2

Immediate-Release Formulation Has Different Dosing Requirements

While immediate-release bupropion exists and can theoretically be used, your proposed conversion is not appropriate:

• Immediate-release bupropion requires three-times-daily dosing, not twice daily 3, 4, 5
• The maximum single dose of immediate-release bupropion should not exceed 150 mg to minimize seizure risk 1
• Your proposed 75 mg BID dosing (150 mg total daily) represents a 50% dose reduction from her current regimen, which may lead to loss of therapeutic effect

What You Should Do Instead

Appropriate Management Options

While awaiting the swallowing evaluation, consider these evidence-based alternatives:

1. Switch to a different antidepressant formulation that comes in smaller tablets or liquid form if available and clinically appropriate

2. If continuing bupropion is essential, switch to the sustained-release (SR) formulation at equivalent dosing:

   • Wellbutrin SR 150 mg once daily (same total daily dose as her current XL)
   • SR tablets are smaller than XL and may be easier to swallow
   • Still cannot be crushed or chewed 1
   • The FDA label states: "When switching patients from WELLBUTRIN Tablets to Wellbutrin XL or from WELLBUTRIN SR Sustained-Release Tablets to Wellbutrin XL, give the same total daily dose when possible" 1

3. Consider switching to immediate-release bupropion ONLY if:

   • Dosed correctly at three times daily (e.g., 50 mg TID for 150 mg total daily dose)
   • Patient understands tablets must be swallowed whole
   • You accept the increased dosing frequency burden
   • One retrospective study showed conversion from SR to IR was generally safe when done properly 6, though this involved equal individual doses and frequencies

Critical Safety Considerations

Monitor for seizure risk factors 7:

• Bupropion lowers seizure threshold
• Risk increases with higher single doses
• Contraindicated in patients with seizure disorders, eating disorders, or abrupt discontinuation of alcohol/benzodiazepines
• The maximum recommended single dose varies by formulation

Document your clinical reasoning for any formulation change, including:

• Why continuing bupropion is necessary versus switching to another antidepressant class
• Discussion with patient about swallowing whole tablets
• Plan for definitive management after swallowing evaluation

Bottom Line

The patient's difficulty swallowing requires a solution, but crushing or chewing any bupropion formulation is absolutely contraindicated due to seizure risk. If she cannot swallow the XL tablet whole, either switch to a different antidepressant entirely or use properly dosed immediate-release bupropion three times daily (swallowed whole). The swallowing evaluation will guide definitive long-term management.